At the last check on Friday, Cognition Therapeutics Inc.’s (NASDAQ:CGTX) stock was up $0.29, moving up 15.03 percent to $2.22. The average number of shares traded per day over the past five days has been 210,942 shares. 5 times new highs have been achieved over the past 5 days, with a $0.8600 gain in that time frame. In the last twenty days, the average volume was 179,870, while in the previous 50 days, it was 110,690.
Since last month, CGTX stock rose 12.87%. Shares of the company fell to $1.0700 on 11/10/22, the lowest level in the past month. A 52-week high of $9.82 was reached on 01/04/22 after having rallying from a 52-week low of $1.07. Since the beginning of this year, CGTX’s stock price has dropped by -69.46% or -$4.1200, and marked a new high 2 times. However, the stock has declined by -77.39% since its 52-week high.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
CGTX stock investors should be aware that Cognition Therapeutics Inc. (CGTX) stock had its last reported insider trading activity 10 days ago on Nov 15. Ricciardi Lisa, the CEO & President of the company, purchased of 12,000 shares for $1.30 on Nov 15. It resulted in a $15,600 investment by the insider. Wallace Peggy added 12,500 shares at an average price of $1.20 on Nov 15. The insider now owns 37,961 shares following the transaction.
In the three months ended June 29, Cognition Therapeutics Inc.’s quick ratio stood at 4.20, while its current ratio was 4.20, showing that the company is able to pay off its debt. Based on annual data, CGTX earned $0.89 million in gross profit and brought in $28.6 million in revenue.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. While analysts expected Cognition Therapeutics Inc. to report -$0.32 quarterly earnings, the actual figure was -$0.25 per share, beating the consensus estimate by 21.90%. During the quarter, the company generated -$12.56 million in EBITDA. The liabilities of Cognition Therapeutics Inc. were 14.24 million at the end of its most recent quarter ended June 29, and its total debt was $0.97 million. The value of shareholders’ equity is $23.97 million.
This quick technical analysis looks at Cognition Therapeutics Inc.’s (CGTX) price momentum. With a historical volatility rate of 117.18%, the RSI 9-day stood at 75.82% on 23 November.
With respect to its five-day moving average, the current Cognition Therapeutics Inc. price is up by +64.18% percent or $0.8600. At present, CGTX shares trade +26.44% above its 20-day simple moving average and -10.20% percent below its 100-day simple moving average. However, the stock is currently trading approximately +17.65% above its SMA50 and -46.60% below its SMA200.
Stochastic coefficient K was 97.07% and Stochastic coefficient D was 89.65%, while ATR was 0.2372. Given the Stochastic reading of 95.76% for the 14-day period, the RSI (14) reading has been calculated as 67.73%. As of today, the MACD Oscillator reading stands at 0.3578, while the 14-day reading stands at 0.4386.
Oppenheimer launched its rating on Cognition Therapeutics Inc. (NASDAQ: CGTX) to an Outperform in a note to investors on November 03, 2021. Cognition Therapeutics Inc. (CGTX) has been rated Buy by analysts. According to 0 brokerage firms, CGTX is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Cognition Therapeutics Inc. stock as buy, with 3 recommending it as overweight.
With a median target price of $10.00, the current consensus forecast for the stock is $9.00 – $10.00. Based on these forecasts, analysts predict Cognition Therapeutics Inc. (CGTX) will achieve an average price target of $9.67.